TLSI Stock Overview
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TriSalus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.34 |
| 52 Week High | US$16.24 |
| 52 Week Low | US$3.32 |
| Beta | 0.65 |
| 1 Month Change | -4.69% |
| 3 Month Change | 2.86% |
| 1 Year Change | -9.41% |
| 3 Year Change | -4.11% |
| 5 Year Change | n/a |
| Change since IPO | -11.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | 0.5% | -0.7% |
| 1Y | -9.4% | 1.2% | 22.8% |
Return vs Industry: TLSI underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: TLSI underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| TLSI volatility | |
|---|---|
| TLSI Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLSI has not had significant price volatility in the past 3 months.
Volatility Over Time: TLSI's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 112 | Mary Szela | trisaluslifesci.com |
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.
TriSalus Life Sciences, Inc. Fundamentals Summary
| TLSI fundamental statistics | |
|---|---|
| Market cap | US$249.12m |
| Earnings (TTM) | -US$63.28m |
| Revenue (TTM) | US$18.51m |
13.5x
P/S Ratio-3.9x
P/E RatioIs TLSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLSI income statement (TTM) | |
|---|---|
| Revenue | US$18.51m |
| Cost of Revenue | US$2.61m |
| Gross Profit | US$15.91m |
| Other Expenses | US$79.18m |
| Earnings | -US$63.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.36 |
| Gross Margin | 85.93% |
| Net Profit Margin | -341.83% |
| Debt/Equity Ratio | 0% |
How did TLSI perform over the long term?
See historical performance and comparison